News & Updates
Filter by Specialty:
Neoadjuvant regorafenib, nivolumab, SCRT combination looks good for rectal cancer
Treatment with the combination of regorafenib, nivolumab, and short-course radiotherapy (SCRT) in the neoadjuvant setting has induced response in stage II-III rectal adenocarcinoma in the phase II REGINA trial, meeting the predefined statistical criteria.
Neoadjuvant regorafenib, nivolumab, SCRT combination looks good for rectal cancer
22 Aug 2024
Simple tests predict liver stiffness in people living with HIV, liver disease
A recent study has noted the excellent specificity and negative predictive value of FIB-4 and nonalcoholic fatty liver disease (NAFLD) fibrosis score (NFS) in diagnosing advanced fibrosis (AF, bridging fibrosis or cirrhosis) among people living with HIV (PWH).
Simple tests predict liver stiffness in people living with HIV, liver disease
22 Aug 2024
Cervical cancer: PFS advantage with pembrolizumab plus CCRT consistent in Asians
Patients with high-risk locally advanced cervical cancer in East Asia get progression-free survival (PFS) boost with pembrolizumab plus concurrent chemoradiotherapy (CCRT), similar to those observed in the overall population of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.
Cervical cancer: PFS advantage with pembrolizumab plus CCRT consistent in Asians
21 Aug 2024
STARGLO shines on first CD20xCD3 BsAb for DLBCL
The addition of glofitamab – a CD20xCD3 T-cell engaging bispecific antibody (BsAb) – to gemcitabine and oxaliplatin (GemOx) chemotherapy improves survival in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) who have received at least one prior line of systemic therapy and are ineligible for autologous stem cell transplant, findings from the phase III STARGLO trial have shown.